The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Diabetic Kidney Disease
Abstract
Diabetes is a major public health challenge and diabetic kidney disease (DKD), a broader diagnostic term than diabetic nephropathy, is the leading cause of chronic kidney disease and end-stage kidney disease in the United States and worldwide. A better understanding of the underlying pathophysiological mechanisms of DKD, and recent clinical trials testing new therapeutic interventions, have shown promising results to curb this epidemic. Given the global health burden of DKD, it is extremely important to prioritize prevention, early recognition, referral, and aggressive management of DKD in the primary care setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Epidemiology of Diabetes and Diabetes-Related Complications
Deshpande, A. D., Harris-Hayes, M., & Schootman, M. (2008) · Physical Therapy · doi:10.2522/ptj.20080020 · Cited by 1,773
Social determinants of health and diabetes: A scientific review
Hill-Briggs, F., Adler, N. E., Berkowitz, S. A., Chin, M. H., Gary-Webb, T. L., Navas-Acien, A., Thornton, P. L., & Haire-Joshu, D. (2021) · Diabetes Care · doi:10.2337/dci20-0053 · Cited by 1,732
Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.003 · Cited by 1,452
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Update on Diabetic Nephropathy: Core Curriculum 2018
Umanath, K., & Lewis, J. B. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.10.026 · Cited by 982
de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022) · Diabetes Care · doi:10.2337/dci22-0027 · Cited by 919
CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease
Anders, H.-J., Huber, T. B., Isermann, B., & Schiffer, M. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0001-y · Cited by 796
Bundy, J. D., Li, C., Stuchlik, P., Bu, X., Kelly, T. N., Mills, K. T., He, H., Chen, J., Whelton, P. K., & He, J. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.1421 · Cited by 783
Delgado, C., Baweja, M., Crews, D. C., Eneanya, N. D., Gadegbeku, C. A., Inker, L. A., Mendu, M. L., Miller, W. G., Moxey-Mims, M. M., Roberts, G. V., et al. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.08.003 · Cited by 783
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Thomas, M. C., Cooper, M. E., & Zimmet, P. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.173 · Cited by 742
The Global Epidemiology of Diabetes and Kidney Disease
Koye, D. N., Magliano, D. J., Nelson, R. G., & Pavkov, M. E. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.10.011 · Cited by 686
The pathogenesis of diabetic nephropathy
Dronavalli, S., Duka, I., & Bakris, G. L. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0894 · Cited by 625
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 516
Obesity and Obesity-Initiated Metabolic Syndrome: Mechanistic Links to Chronic Kidney Disease
Wahba, I. M., & Mak, R. H. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04071206 · Cited by 513
Pedrini, M. T., Levey, A. S., Lau, J., Chalmers*, T. C., & Wang, P. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-7-199604010-00002 · Cited by 496
Meyer, T. W., Bennett, P. H., & Nelson, R. G. (1999) · Diabetologia · doi:10.1007/s001250051447 · Cited by 445
Renal protective effect of enalapril in diabetic nephropathy.
Bjorck, S., Mulec, H., Johnsen, S. A., Norden, G., & Aurell, M. (1992) · BMJ · doi:10.1136/bmj.304.6823.339 · Cited by 432
Vascular Complications of Diabetes
Beckman, J. A., & Creager, M. A. (2016) · Circulation Research · doi:10.1161/circresaha.115.306884 · Cited by 412
Kasiske, B., Lakatua, J., Ma, J., & Louis, T. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v31.pm9631839 · Cited by 408
LEVEY, A. S., GREENE, T., BECK, G. J., CAGGIULA, A. W., KUSEK, J. W., HUNSICKER, L. G., & KLAHR, S. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v10112426 · Cited by 399
Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan
Vogt, L., Waanders, F., Boomsma, F., de Zeeuw, D., & Navis, G. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007060693 · Cited by 372
de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022) · Kidney International · doi:10.1016/j.kint.2022.08.012 · Cited by 353
Diagnosis and Management of Type 2 Diabetic Kidney Disease
Doshi, S. M., & Friedman, A. N. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11111016 · Cited by 344
Diabetes and its drivers: the largest epidemic in human history?
Zimmet, P. Z. (2017) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0039-3 · Cited by 338
Toyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M. J., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13648 · Cited by 330
Kidokoro, K., Cherney, D. Z. I., Bozovic, A., Nagasu, H., Satoh, M., Kanda, E., Sasaki, T., & Kashihara, N. (2019) · Circulation · doi:10.1161/circulationaha.118.037418 · Cited by 283
Shaman, A. M., Bain, S. C., Bakris, G. L., Buse, J. B., Idorn, T., Mahaffey, K. W., Mann, J. F. E., Nauck, M. A., Rasmussen, S., Rossing, P., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.055459 · Cited by 255
Lee, A. K., Warren, B., Lee, C. J., McEvoy, J. W., Matsushita, K., Huang, E. S., Sharrett, A. R., Coresh, J., & Selvin, E. (2018) · Diabetes Care · doi:10.2337/dc17-1669 · Cited by 226
Yau, K., Dharia, A., Alrowiyti, I., & Cherney, D. Z. I. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.04.094 · Cited by 223
SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome
van Bommel, E. J. M., Muskiet, M. H. A., Tonneijck, L., Kramer, M. H. H., Nieuwdorp, M., & van Raalte, D. H. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06080616 · Cited by 222
Pathogenesis of diabetic nephropathy
Cao, Z., & Cooper, M. E. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00131.x · Cited by 219
Podocytes: the Weakest Link in Diabetic Kidney Disease?
Lin, J. S., & Susztak, K. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0735-5 · Cited by 189
All-cause costs increase exponentially with increased chronic kidney disease stage.
Golestaneh, L., Alvarez, P. J., Reaven, N. L., Funk, S. E., McGaughey, K. J., Romero, A., Brenner, M. S., & Onuigbo, M. A. C. (2017) · PubMed · Cited by 173
Self-citationLazarus, B., Wu, A., Shin, J.-I., Sang, Y., Alexander, G. C., Secora, A., Inker, L. A., Coresh, J., Chang, A. R., & Grams, M. E. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.0292 · Cited by 167
Reversibility of Structural and Functional Damage in a Model of Advanced Diabetic Nephropathy
Pichaiwong, W., Hudkins, K. L., Wietecha, T., Nguyen, T. Q., Tachaudomdach, C., Li, W., Askari, B., Kobayashi, T., O’Brien, K. D., Pippin, J. W., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012050445 · Cited by 160
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Górriz, J. L., Soler, M. J., Navarro-González, J. F., García-Carro, C., Puchades, M. J., D’Marco, L., Martínez Castelao, A., Fernández-Fernández, B., Ortiz, A., Górriz-Zambrano, C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040947 · Cited by 144
The Renin-Angiotensin System and Diabetic Nephropathy
Gurley, S. B., & Coffman, T. M. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.01.009 · Cited by 144
for the Renal Insufficiency And Cardiovascular Events (RIACE) Study Group, Penno, G., Solini, A., Orsi, E., Bonora, E., Fondelli, C., Trevisan, R., Vedovato, M., Cavalot, F. L., Lamacchia, O., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4691-2 · Cited by 137
Nauck, M. A., Stewart, M. W., Perkins, C., Jones-Leone, A. R., Yang, F., Perry, C., Reinhardt, R. R., & Rendell, M. (2015) · Diabetologia · doi:10.1007/s00125-015-3795-1 · Cited by 135
Epstein, M., Kovesdy, C. P., Clase, C. M., Sood, M. M., & Pecoits‐Filho, R. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.04.016 · Cited by 134
Bays, H. E. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0042-y · Cited by 121
Management of Obesity in Adults with CKD
Friedman, A. N., Kaplan, L. M., le Roux, C. W., & Schauer, P. R. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020101472 · Cited by 107
Verma, S., Bhatt, D. L., Bain, S. C., Buse, J. B., Mann, J. F. E., Marso, S. P., Nauck, M. A., Poulter, N. R., Pratley, R. E., Zinman, B., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.033898 · Cited by 105
The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis
Luther, J. M., & Fogo, A. B. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.006 · Cited by 98
Diabetic Kidney Disease: A Syndrome Rather Than a Single Disease
Piccoli, G. B., Grassi, G., Cabiddu, G., Nazha, M., Roggero, S., Capizzi, I., Pascale, A. D., Priola, A. M., Vico, C. D., Maxia, S., et al. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.87 · Cited by 90
Nationwide multicentre kidney biopsy study of Japanese patients with type 2 diabetes
Furuichi, K., Yuzawa, Y., Shimizu, M., Hara, A., Toyama, T., Kitamura, H., Suzuki, Y., Satō, H., Uesugi, N., Ubara, Y., et al. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw417 · Cited by 88
Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
Rabizadeh, S., Nakhjavani, M., & Esteghamati, A. (2019) · Intern J Endocrinol Metab · doi:10.5812/ijem.84353 · Cited by 81
New progress in drugs treatment of diabetic kidney disease
Wang, J., Xiang, H., Lu, Y., Wu, T., & Ji, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111918 · Cited by 74
The 2020 Updated KDOQI Clinical Practice Guidelines for Nutrition in Chronic Kidney Disease
Ikizler, T. A., & Cuppari, L. (2021) · Blood Purification · doi:10.1159/000513698 · Cited by 73
Folkerts, K., Petruski‐Ivleva, N., Kelly, A., Fried, L. F., Blankenburg, M., Gay, A., & Kovesdy, C. P. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.12.1506 · Cited by 62
Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease
Nakamura, T., Girerd, S., Jaisser, F., & Barrera‐Chimal, J. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.004 · Cited by 58
Ravera, M., Ratto, E., Vettoretti, S., Parodi, D., & Deferrari, G. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004110957 · Cited by 52
Advanced-Glycation End-Products Induce Podocyte Injury and Contribute to Proteinuria
Nishad, R., Tahaseen, V., Kavvuri, R., Motrapu, M., Singh, A., Peddi, K., & Pasupulati, A. K. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.685447 · Cited by 52
Barton, M., & Tharaux, P. (2012) · Clinical Kidney Journal · doi:10.1093/ckj/sfs001 · Cited by 50
Jolly, S. E., Li, S., Chen, S., Narva, A. S., Jurkovitz, C. T., Norris, K. C., & Shlipak, M. G. (2008) · American Journal of Nephrology · doi:10.1159/000174857 · Cited by 30
Diabetic nephropathy in American Indians, with a special emphasis on the pima Indians
Pavkov, M. E., Knowler, W. C., Hanson, R. L., & Nelson, R. G. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0083-1 · Cited by 28
Pathophysiology of Diabetic Kidney Disease
Qaz, M., Sawaf, H., Ismail, J., Qazi, H., & Vachharajani, T. J. (2022) · EMJ Nephrology · doi:10.33590/emjnephrol/22-00060 · Cited by 28
Rikin, S., Deccy, S., Zhang, C., Crandall, J. P., Deng, Y., & Golestaneh, L. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07863-0 · Cited by 22
Self-citationGuideline on the Primary Prevention of Cardiovascular Disease: Let's Get It Into Practice!
Coke, L. A., & Himmelfarb, C. D. (2019) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000000586 · Cited by 19
Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus
Betteridge, J. D. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.09.013 · Cited by 18
AKI-to-CKD transition is a potential mechanism for non-albuminuric diabetic kidney disease
Lee, K., & He, C. (2022) · Faculty Reviews · doi:10.12703/r/11-21 · Cited by 11
The ROADMAP trial: olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
Grassi, G. M. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.602068 · Cited by 9
DAPA-CKD: Significant Victory for CKD with or without Diabetes
Patel, A. B., Mistry, K., & Verma, A. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.02.007 · Cited by 9
Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes
Perkins, B. A., Bebu, I., de Boer, I. H., Molitch, M. E., Zinman, B., Bantle, J. P., Lorenzi, G. M., Nathan, D. M., & Lachin, J. M. (2022) · Diabetes Care · doi:10.2337/dc22-1420 · Cited by 8
Scheen, A. J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.05.82 · Cited by 6
Cited by
Zhu, Y., Zhang, Y., Yang, M., Tang, N., Liu, L., Wu, J., & Yang, Y. (2024) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s458263 · Cited by 14
Du, Z., Liu, X., Li, J., Min, H., Ma, Y., Hua, W., Zhang, L., Zhang, Y., Shang, M., Chen, H., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02404-z · Cited by 6
Metadata
- Authors
- Gupta, S., Dominguez, M., & Golestaneh, L.
- Venue
- Medical Clinics of North America
- Publisher
- Elsevier BV
- Published
- 2023-07
- Volume
- 107
- Issue
- 4
- Pages
- 689-705
- ISSN
- 0025-7125 (ISSN-L)
- OpenAlex
- W4362704620
- Cited by
- 337
- References
- 79
- FWCI
- 55.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.